NCT04728269已完成不适用
Exploratory Study to Assess the Impact of a Cosmetic Product (Lactibiane Topic AD) on Skin Flora and Skin Reinforcement Barrier in Mild to Moderate Atopic Dermatitis
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- PiLeJe
- 入组人数
- 10
- 试验地点
- 2
- 主要终点
- Change in skin flora composition
研究概览
简要总结
This exploratory study aims to evaluate the impact of a cosmetic product (Lactibiane Topic AD) vs placebo on skin flora and skin reinforcement barrier in mild to moderate atopic dermatitis using biometrological, biological and clinical parameters.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject diagnosed with mild to moderate AD defined as SCORAD≤40 (Eichenfield et al. JAAD 2014).
- •Subject with at least two symmetric AD lesions with comparable severity: Located either on upper extremities (left and right arms except hands) or lower extremities (left and right legs except feet), With an erythema ≥ 1 (mild to severe intensity), With a lesional area score ≥ 4 on both lesions with an authorized delta of two points between the two lesions, With a sufficient extent to allow all the investigations.
- •Subject with I, II, III or IV skin phototype (according to Fitzpatrick's scale).
- •For woman of childbearing potential (defined as all women physiologically capable of becoming pregnant): Negative urine pregnancy test at inclusion visit. Use of a highly effective method of birth control* during the study. * A highly effective method of birth control is defined as one which results in a low failure rate (less than 1%) when used consistently and correctly, such as implants, combined oral contraceptives, intrauterine device, double barrier methods (e.g. condom with spermicide), sexual abstinence or vasectomized partner.
- •Subject with health insurance coverage according to local regulation.
- •Subject having given his written informed consent.
排除标准
- •Subject having a known hypersensitivity, allergy or contraindication to any ingredients contained within the investigational product or placebo.
- •Subject having exposed his skin to natural or artificial UV within 8 weeks prior to the inclusion visit or intending to expose his skin during the study.
- •Subject having performed phototherapy within 8 weeks prior to the inclusion visit or intending to perform phototherapy during the study.
- •Subject having performed another physical treatment (e.g radiotherapy...) on the investigational areas within 6 months prior to the inclusion visit or intending to perform it during the study.
- •Subject treated with systemic non-steroidal anti-inflammatory drugs (≥3 days) within 1 week before the inclusion visit.
- •Subject treated with biological immunosuppressive drugs within 12 weeks prior to the inclusion visit or intending to be treated with it during the study.
- •Subject treated with non-biological immunosuppressive drugs within 4 weeks prior to the inclusion visit or intending to be treated with it during the study.
- •Subject treated with systemic corticoids within 1 week prior to the inclusion visit or planed during the study.
- •Subject treated with systemic antibiotics within 7 days prior to the inclusion visit or planed during the study.
- •Subject having applied topical immunomodulators, non-steroidal anti-inflammatory, corticoids or antihistamines on investigational limbs within 1 weeks prior to the inclusion visit.
- •Subject having applied topical antibiotics or disinfectants on investigational limbs within 2 weeks prior to the inclusion visit.
- •Subject having applied any other topical and/or care product after the last grooming prior to the inclusion visit.
- •Subject having applied water or care product (except hands cleaning) within 12 hours prior to the inclusion visit.
- •Subject having started, modified or stopped any other treatment/product within 4 weeks prior to the inclusion visit or intending to do so during the study that according to the investigator's judgment, could interfere with study results.
- •Subject having significant medical condition that according to the investigator's judgment, deems inappropriate for study participation (e.g present or past malignancy, present or past skin condition...).
- •Subject having significant dermatological condition or sign (e.g disease, scare, abundant hairiness, tanning mark...) that according to the investigator's judgment, could limit the observations or/and interfere with the interpretations.
- •Subject taking part or having participated in another clinical study within 2 weeks prior to the inclusion visit.
- •Subject under legal guardianship or incapacitation.
- •Subject linguistically or psychologically unable of signing informed consent form and unable to comply with the protocol requirements according to the investigator's judgment.
结局指标
主要结局
Change in skin flora composition
时间窗: from baseline (Day 0) at Day 14
16S rRNA sequencing, qPCR
次要结局
- Clinical severity of lesional areas(Day 0, Day 14, Day 21)
- SCORing Atopic Dermatitis(Day 0, Day 14, Day 21)
- Manifestation of adverse local reactions(From Day 0 to Day 21)
- Skin barrier status(Day 0, Day 14, Day 21)
- Patient Oriented SCORing Atopic Dermatitis(Day 0, Day 14, Day 21)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Impact of a Topical Cosmetic Product on Women's HairHair ThinningHair LossNCT06060834University of Memphis14
已完成
不适用
Efficacy Evaluation of the Activity of a Cosmetic Product (Topical Use) on Hair Regrowth vs PlaceboHypertrichosisNCT03273504Derming SRL24
已完成
不适用
Clinical and Biological Anti-aging Efficacy of a Cosmetic CreamAnti-agingNCT05895591Pierre Fabre Dermo Cosmetique33
已完成
不适用
Cosmetic Study to Improve the Appearance of Skin Afflicted With Mild to Moderate Atopic Dermatitis.Atopic Dermatitis EczemaNCT03268174AOBiome LLC19
已完成
不适用
Assessment of Skin Tolerance and Efficacy of a Cosmetic Product After 5 Days of Use on Subjects With Atopic DermatitisAtopic DiathesisEczema-prone SkinNCT05807113Bionorica SE44